Spluttering US Generics Landscape Shows Signs Of Promise In Q2
Teva, Sandoz, Viatris Make Positive Noises In Q2 Readout
Executive Summary
High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.